Abstract: The present invention relates to L-glutamate-derived compounds of general formula (1) in which the R radical is a linear or branched C5 to C2 alkyl group, .—or the benzyl radical, .—or the phenethyl radical, for topical use as a medicament (or as a dermatological active ingredient) intended for the treatment and/or prevention of inflammatory dermatoses.

Abstract: The present invention relates to Formula (I), wherein—if X=NH, each of R1, R2, R3, R4 represents a hydrogen atom; if X=N, the core is aromatic, and R2, R3 and R4 represent hydrogen atoms, and R1=H, halogen, aryl, heteroaryl, alkenyl or acetylenyl; or R1, R2, R3, R4 are defined such that R1 or R2 or R3 or R4 represents a methyl group, and the three other radicals represent a hydrogen atom.

Abstract: The invention relates to a medicament comprising at least one reducing alkyl-sugar monomer having a hydroxyl function which is substituted by an alkoxy radical at C2-C40, said medicament being preferably intended to regulate inflammatory mechanisms. The reducing sugar is preferably selected from the group containing rhamnose, fucose and glucose. The invention also relates to a cosmetic treatment method involving the topical application of a composition comprising at least one reducing alkyl-sugar monomer having a hydroxyl function which is substituted by an alkoxy radical at C2-C40.

Abstract: The present invention relates to a novel bacterial strain isolated from groundwater. The invention also relates to bacterial extracts and to the use of same in the context of the treatment of inflammations. More particularly, the present invention relates to novel compositions of interest in the treatment and the prevention of inflammatory disorders, notably dermatological pathologies.

Abstract: Disclosed is a method of treating seborrhoea by administering to an patient in need thereof a therapeutically effective amount of 2,3-dihydroxypropyl dodecanoate. In particular, the seborrhoea is associated with the skin, including the scalp. The method topically applies a composition containing a therapeutically effective amount of 2,3-dihydroxypropyl dodecanoate to the skin.

Abstract: The present invention relates to a novel bacterial strain isolated from groundwater. The invention also relates to bacterial extracts and to the use of same in the context of the treatment of inflammations. More particularly, the present invention relates to novel compositions of interest in the treatment and the prevention of inflammatory disorders, notably dermatological pathologies.

Abstract: The invention relates to zinc coceth sulfate for the use thereof as an antibacterial agent for treating skin disorders associated with Propionibacterium acnes.

Abstract: The invention relates to a dermatological composition containing a myrtle extract in a concentration that is higher than or equal to 0.01 wt.%, for the use thereof as an anti-biofilm agent against Propionibacterium acnes.

Abstract: The invention relates to a hypoallergenic dermatological composition comprising an extract of aerial part of cereal or pseudocereal, excluding the grains, for use in persons allergic to cereals.

Abstract: The inventive compositions for topical application are characterized in that they comprises one or several hyaluronate fragments in the form of a main principle whose molecular weight ranges from 50 000 and 750 000 Da and a retinoid if necessary.

Abstract: The present invention relates to a cosmetic or pharmaceutical composition for cutaneous application, whose goal is the depigmentation of the skin.

Abstract: The invention concerns the use of a cosmetic compound to improve hair strength, said cosmetic compound comprising as an active ingredient an extract of Balanites almonds.

Abstract: The invention relates to compound of generic formula (I) in which: R1 and R2 represent: OH, a hydrogen atom, a C1-C6 alkyl radical a C1-C6 alkoxy radical, a halogen, or OCOR3; R3 represents: a C1-C24 alkyl radical a C12-C24 alkenyl radical comprising at least one unsaturation; R4 represents: COR5, a glucide substituted or not by one or more acetyl radical(s); R5 represents: a C10-C24 alkyl radical or a C12-C24 alkenyl radical comprising at least one unsaturation; R6 and R7 represent:—simultaneously a hydrogen atom or a methyl radical, or—when R6 represents a hydrogen atom, R7 represents a C1-C6 alkyl radical or a phenyl substituted or not by one or more C1-C3 alkoxy radical(s) or one or more halogen(s) or—R6 and R7 are bonded together and form a C3-C6 cycloalkyl, and pharmaceutically or cosmetically acceptable salts.

Abstract: The present invention relates to a compound of the general formula (I) where: X?S, SO or SO2; and one of the radicals R1 and R2 is a hydrogen atom and the other is a radical: a C1 to C18 linear or branched alkyl, optionally substituted by one or more halogen atom(s); a C2 to C18 linear or branched alkenyl, optionally substituted by one or more halogen atom(s); an aralkyl, optionally substituted by one or more C1 to C6 alkoxy group(s); or a COR3 or CONHR3, but not simultaneously, where R3 is a radical: a C1 to C18 linear or branched alkyl, optionally substituted by one or more halogen atom(s); a C2 to C18 linear or branched alkenyl, optionally substituted by one or more halogen atom(s); an aralkyl, optionally substituted by one or more C1 to C6 alkoxy group(s); an aralkenyl, optionally substituted by one or more C1 to C6 alkoxy groups and/or one or more OH group(s); or an aryl radical, optionally substituted by one or more C1 to C6 alkoxy group(s).

Abstract: A method for high temperature sterilization of an emulsion, in particular a dermocosmetic preparation. The method comprises the steps of gradually pre-heating, performing ultra-high temperature sterilization and gradually cooling the emulsion. The emulsion is heated up to a pre-heating temperature, which is the temperature of the emulsion at the stability limit. Ultra-high temperature sterilization is performed by infusion of the pre-heated emulsion by heating the emulsion up to a sterilization temperature, maintaining the emulsion at the sterilization temperature, and cooling the emulsion under a vacuum at an end-of-sterilization temperature. The emulsion is gradually cooled with agitation to a storage temperature.

Abstract: The present invention relates to a compound with the following general formula (I): in which: R1 is a hydrocarbon chain of an unsaturated fatty acid from C12 to C24 including at least one unsaturation; and R2 and R3 are, independently or simultaneously: a hydrogen or a C1-C3 alkyl or a phenyl; and R4: a hydrogen atom or COR1?, where R1? is a hydrocarbon chain of an unsaturated fatty acid from C12 to C24 including at least one unsaturation, advantageously 1 to 6 and preferably 1 to 4.

Abstract: The invention relates to a sucrose octasulfate of magnesium, having general formula I, the preparation method thereof and the use of same in the pharmaceutical and/or cosmetic field, wherein 0?n?4, n is an integer and Y represents OH, Cl, Br, I, NO3, C6H5O7, CH3CO2, CF3CO2 or —OCH3.

Abstract: The invention relates to a compound of general formula (I) characterized in that: R1 is a C1-C4 alkyl group, and R2 is an optionally substituted nitrogen, sulfur or oxygen containing heteroaromatic ring.

Abstract: The present invention relates to the activation of peptidyl arginine deiminase (PADs) 1 and/or 3 in the epidermis by at least one active agent used alone or in combination, namely caffeine, acefylline and/or theobromine in a cosmetic and/or pharmaceutical composition. The present invention also relates to the use of the aforementioned active agents in cosmetics and/or therapeutics, alone or in combination, in order to improve the barrier functions of the epidermis, to prevent and/or treat symptoms related to dry skin or to improve and/or promote hydration of the keratinous layer. Finally, the invention relates to increasing the activity of PAD1 and/or PAD3 in the epidermis.

Abstract: The invention relates to a dermatological composition for the prevention and/or treatment of rosacea, of couperose or of skin which exhibits diffuse redness or small dilated vessels, characterized in that it contains: -at least one interference pigment comprising titanium dioxide-coated mica, transmitting a colour complementary to red; -at least one sunscreen that is active in the UVA and UVB ranges; -one or more soothing and/or moisturizing active ingredients; and -the rest as dermatologically acceptable excipient(s) necessary for formulating said composition.